Bluebird Revises Business Priorities And Secures Upfront Cash From Bristol

 
• By Jessica Merrill

The company is deferring investment in a US commercial team and prioritizing R&D activities, but it outlined an accelerated path to approval for LentiGlobin in sickle cell disease.

SC2005_Revision_595738937_1200.jpg
Bluebird revised some of its business operations through 2022 • Source: Shutterstock

More from Strategy

More from Business